{"id":8317,"date":"2014-09-22T00:00:00","date_gmt":"2014-09-21T22:00:00","guid":{"rendered":"https:\/\/idibell.cat\/blog\/2014\/09\/22\/neix-xenopat-que-ofereix-models-de-ratolins-per-al-tractament-personalitzat-del-cancer-models-ortotopics-i-medicina-personalitzada-els-socis-del-laboratori-a-lempresa\/"},"modified":"2020-08-07T10:41:24","modified_gmt":"2020-08-07T08:41:24","slug":"neix-xenopat-que-ofereix-models-de-ratolins-per-al-tractament-personalitzat-del-cancer-models-ortotopics-i-medicina-personalitzada-els-socis-del-laboratori-a-lempresa","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2014\/09\/neix-xenopat-que-ofereix-models-de-ratolins-per-al-tractament-personalitzat-del-cancer-models-ortotopics-i-medicina-personalitzada-els-socis-del-laboratori-a-lempresa\/","title":{"rendered":"Neix XenOPAT, que ofereix models de ratolins per al tractament personalitzat del c\u00e0ncer Models ortot\u00f2pics i medicina personalitzada Els socis Del laboratori a l\u2019empresa"},"content":{"rendered":"<p>El passat 8 de setembre es va constituir l\u2019empresa XenOPAT S.L., una spin-off de l\u2019Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), l\u2019Institut Catal\u00e0 d\u2019Oncologia (ICO) <span style=\"color: #58585a; font-family: Arial; font-size: 12px; text-align: justify;\">i l&#8217;Hospital Universitari de Bellvitge<\/span>amb la vocaci\u00f3 de fer arribar a la societat els darrers aven\u00e7os cient\u00edfics al servei de la lluita contra el c\u00e0ncer amb dues branques principals: el desenvolupament de nous f\u00e0rmacs i<\/p>\n<p>avan\u00e7ar en la implementaci\u00f3 de tractaments oncol\u00f2gics personalitzats.<\/p>\n<p>Els serveis de XenOPAT es basen en l\u2019\u00fas de models ortot\u00f2pics (orthoxenograft\u00ae) de ratol\u00ed mitjan\u00e7ant la implantaci\u00f3 de petits fragments de tumors humans en l\u2019\u00f2rgan corresponent del ratol\u00ed. Aix\u00ed, per exemple, s\u2019implanta un tumor d\u2019ovari hum\u00e0 a l\u2019ovari del ratol\u00ed. D\u2019aquesta manera, el model animal reprodueix les caracter\u00edstiques histol\u00f2giques, gen\u00e8tiques i epigen\u00e8tiques dels tumors humans, aix\u00ed com els patrons de disseminaci\u00f3 del tumor, cosa que no s&#8217;aconsegueix amb altres m\u00e8todes d&#8217;implantaci\u00f3.<\/p>\n<p>Pel que fa el desenvolupament de nous f\u00e0rmacs, XenOPAT posa a disposici\u00f3 d\u2019investigadors, per\u00f2 sobretot d\u2019empreses que estiguin desenvolupant nous f\u00e0rmacs, un banc de desenes de models de ratolins ortot\u00f2pics que reprodueixen diferents tipus de tumors caracteritzats a nivell gen\u00e8tic i amb diferents sensibilitats a diverses quimioter\u00e0pies. Aquest banc, anomenat OrthoXenoBank\u00ae, inclou tumors de colon, pulm\u00f3, ovari, endometri, mama, p\u00e0ncrees, tumors germinals, cap i coll, etc. Aix\u00ed XenOPAT ofereix un ampli ventall de possibilitats per testar nous f\u00e0rmacs en models molt avan\u00e7ats, permetent realitzar la millor precl\u00ednica possible, essencial durant el complicat proc\u00e9s de desenvolupament de f\u00e0rmacs.<\/p>\n<p>En l\u2019\u00e0rea de la medicina personalitzada, XenOPAT ofereix la possibilitat de generar un orthoxenograft\u00ae a partir del tumor de un pacient de manera que podrem identificar el tractament que ofereixi les m\u00e0ximes garanties de resposta<\/p>\n<p>per a cada pacient.<\/p>\n<p>XenOPAT \u00e9s fruit del treball realitzat durant molts anys per dos socis que ara han decidit portar la seva recerca al m\u00f3n de l\u2019empresa: l\u2019investigador Alberto Villanuevai el pat\u00f2leg August Vidal. La tercera s\u00f2cia, Anna Portela, s\u2019encarregar\u00e0 de la gesti\u00f3 de l\u2019empresa.<\/p>\n<p>Alberto Villanueva Garatachea Phd., Investigador responsable del Grup de Resist\u00e8ncia Farmacol\u00f2gica i Xenografts de l\u2019ICO-IDIBELL. \u00c9s internacionalment reconegut pels seus treballs en la generaci\u00f3 de models tumorals (Personal Derived Xenofraft (PDX) ortot\u00f2pics i orthoxenografts\u00ae utilitzats tant per a l\u2019estudi dels mecanismes d&#8217;adquisici\u00f3 de resist\u00e8ncia a importants tractaments quimioterap\u00e8utics (cisplat\u00ed, 5-fluroracil i oxaliplat\u00ed), com per al desenvolupament de nous f\u00e0rmacs i tractaments.. Alguns dels models generats pel Dr. Villanueva s\u00f3n \u00fanics en el m\u00f3n. \u00c9s autor de nombroses publicacions cient\u00edfiques.<\/p>\n<p>August Vidal Bel, MD. Pat\u00f2leg facultatiu del Servei d\u2019Anatomia Patol\u00f2gica de l\u2019Hospital Universitari de Bellvitge (HUB). Director del programa d\u2019Anatomia Patol\u00f2gica. Responsable de les \u00e0rees de Patologia ginecol\u00f2gica i Patologia dental i col\u00b7laborador de les \u00e0rees de Patologia urol\u00f2gica i Patologia de cap i coll. Vidal T\u00e9 una \u00e0mplia experi\u00e8ncia en la caracteritzaci\u00f3 histopatol\u00f2gica i gen\u00e8tica dels orthoxenografts\u00ae.<\/p>\n<p>Anna Portela Mestres, PhD, MBA. Llicenciada en Biologia (2001) i Doctora en Gen\u00e8tica (2007) per la Universitat Aut\u00f2noma de Barcelona. Durant el seu doctorat va realitzar diverses estades en centres de prestigi internacional: H\u00f6henheim Universit\u00e4t i Johns Hopkins University. Va realitzar la seva estada postdoctoral (2007-2014) al Grup d\u2019Epigen\u00e8tica del C\u00e0ncer del CNIO i posteriorment al Grup d&#8217;Epigen\u00e8tica del C\u00e0ncer de l\u2019IDIBELL, dirigits pel Dr. Manel Esteller. Durant aquest temps va treballar per comprendre les bases moleculars del c\u00e0ncer i per definir biomarcadors de pron\u00f2stic en diversos tipus de tumors. Paral\u00b7lelament va realitzar un M\u00e0ster en Administraci\u00f3 d\u2019Empreses (MBA) a ESADE (2013).<\/p>\n<p>Amb XenOPAT ja s\u00f3n quatre les spin-off que ha posat en marxa la Unitat d\u2019Innovaci\u00f3 i Transfer\u00e8ncia de l\u2019IDIBELL des de la seva creaci\u00f3 l\u2019any 2010. En aquest temps la Unitat tamb\u00e9 ha sol\u00b7licitat una cinquantena de noves patents i ha llicenciat 11 patents a diverses empreses.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>El passat 8 de setembre es va constituir l\u2019empresa XenOPAT S.L., una spin-off de l\u2019Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), l\u2019Institut Catal\u00e0 d\u2019Oncologia (ICO) i l&#8217;Hospital Universitari de Bellvitgeamb la vocaci\u00f3 de fer arribar a la societat els darrers aven\u00e7os cient\u00edfics al servei de la lluita contra el c\u00e0ncer amb dues branques principals: el desenvolupament [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":10983,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[1,493],"tags":[],"class_list":["post-8317","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sin-categorizar","category-innovacio"],"publishpress_future_action":{"enabled":false,"date":"2024-12-30 06:40:25","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/8317","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=8317"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/8317\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/10983"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=8317"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=8317"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=8317"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}